106724-84-9Relevant articles and documents
HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE
-
Page/Page column 83, (2019/08/12)
This invention relates to novel compounds and pharmaceutical compositions comprising. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.
BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF
-
Page/Page column 53, (2019/02/02)
The invention provides novel compounds having the general formula (I): (I) wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.
BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS
-
Page/Page column 42; 43, (2019/05/07)
The invention provides novel compounds having the general formula (I) or pharmaceutically acceptable salts thereof, wherein RA, RB1, RB2, the A ring and the B ring are as described herein, pharmaceutical compositions inclu
N-[4-OXO-2,3-DIHYDRO-1,5-BENZOXAZEPIN-3-YL]-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOL E-2-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RIP1 KINASE INHIBITORS FOR TREATING E.G. IRRITABLE BOWEL SYNDROME (IBS)
-
Page/Page column 40; 41, (2019/11/12)
The invention provides compounds having the general formula (I): or pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R7a, R7b, X, RB1, RB2, n, p, q, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and the compounds for use as receptor-interacting protein-1 (RIP1) kinase inhibitors in methods of treating e.g. Parkinson's or Alzheimer's disease, irritable bowel disorders (IBD), Crohn's disease, respiratory distress syndrome (ARDS) or chronic obstructive pulmonary disease (COPD). An exemplary compound is e.g. (4S,6S)-4-fluoro-6-phenyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-l,5- benzoxazepin-3-yl]-5,6-dihydro-4H-pyrrolo[l,2-b]pyrazole-2- carboxamide (example 11) with a Ki (uM) in a RIP1 assay of 0.0044 uM..
Synthesis of 1-Alkyl-5-amino-1,2,4-triazoles Based on Nucleophilic Substitution and Reduction Reactions
Tolstyakov
, p. 1537 - 1547 (2019/01/04)
A series of 1-alkyl-5-amino-1H-1,2,4-triazoles were synthesized starting from 3,5-dibromo-1H- 1,2,4-triazole by alkylation and subsequent nucleophilic substitution of the 5-bromine atom by azido group, reduction of the latter to amino group, and hydrodebromination.
Diphenylmethyl and tetrahydropyranyl protecting groups in the synthesis of 3-substituted 5-amino- and 5-hydrazino-1,2,4-triazoles
Tolstyakov,Tselinskii,Dreving
, p. 2179 - 2185 (2008/09/17)
The use of hydrazine as reagent in nucleophilic substitution and reduction in the 1,2,4-triazole series in combination with introduction of labile protecting groups makes it possible to synthesize 5-hydrazino-3-nitro-1H-1,2,4- triazole and 3-chloro-5-hydr
Proton-Ionizable Crown Compounds. 4. New Macrocyclic Polyether Ligands Containing a Triazole Subcyclic Unit
Bradshaw, Jerald S.,Nielsen, Ralph B.,Tse, Pui-Kwan,Arena, Giuseppi,Wilson, Bruce E.,et al.
, p. 361 - 368 (2007/10/02)
A series of macrocyclic polyether (crown) ligands containing the proton-ionizable s-triazole subcyclic unit were prepared by reacting the 1-THP blocked 3,5-bis(chloromethyl)-1H-1,2,4-triazole with various oligoethylene glycols.The starting bis(chloromethy
